Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a nasal spray for intranasal use. It provides rapid vasoconstriction of cranial blood vessels and inhibition of pro‑inflammatory neuropeptide release, delivering acute relief of migraine attacks and cluster headache episodes in adult patients.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches that meet EU regulatory standards. Our distribution network provides reliable logistics and documentation for cross‑border procurement.

Imigran (sumatriptan) acts on the serotonergic pathway to treat acute headache disorders.

- Migraine: rapid relief of moderate to severe migraine attacks with or without aura. - Migraine with aura: alleviates headache and associated neurological symptoms when administered early. - Cluster headache: abortive treatment of acute cluster headache episodes, reducing pain intensity. - Acute episodic cluster headache: provides prompt symptom control during cluster periods. - Acute migraine in adults: effective for single‑episode treatment when other analgesics are insufficient.

Sumatriptan nasal spray may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Taste disturbance: altered or unpleasant taste sensation in the mouth. - Nasal irritation: burning, stinging or discomfort in the nasal passages. - Dizziness: feeling light‑headed or unsteady. - Nausea: mild stomach upset or urge to vomit.

Serious or Rare Side Effects: - Chest pain: sensation of pressure or pain in the chest, indicating possible cardiac effects. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity, or rapid heart rate when combined with serotonergic agents. - Severe allergic reaction: rash, swelling, difficulty breathing or anaphylaxis.

When prescribing Imigran, clinicians should consider several safety precautions to minimize risk. - Cardiovascular disease: avoid use in patients with uncontrolled hypertension, coronary artery disease, or history of myocardial infarction. - Hemiplegic or basilar migraine: contraindicated due to increased risk of cerebrovascular events. - Concomitant serotonergic drugs: caution when combined with SSRIs, SNRIs, or MAO inhibitors because of serotonin syndrome risk. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus; limited data available. - Age considerations: safety and efficacy not established in pediatric patients under 18 years. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight, and retain in original packaging.

Sumatriptan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - SSRIs/SNRIs: increased potential for serotonin syndrome. - Ergotamine derivatives: additive vasoconstrictive effects may cause coronary spasm. - Other triptans: combined use can precipitate excessive vasoconstriction. - Monoamine oxidase inhibitors: similar to MAO inhibitors, avoid co‑administration.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood‑pressure‑lowering effects; monitor blood pressure. - CYP2D6 inhibitors: may increase sumatriptan plasma levels; adjust dose if necessary.